Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. Liebers N, et al. Among authors: middeke jm. Blood Adv. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155. Blood Adv. 2021. PMID: 34196677 Free PMC article.
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Middeke JM, et al. Biol Blood Marrow Transplant. 2017 Sep;23(9):1491-1497. doi: 10.1016/j.bbmt.2017.05.014. Epub 2017 May 17. Biol Blood Marrow Transplant. 2017. PMID: 28527985 Free article. Clinical Trial.
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: middeke jm. Invest New Drugs. 2020 Oct;38(5):1472-1482. doi: 10.1007/s10637-020-00916-3. Epub 2020 Mar 14. Invest New Drugs. 2020. PMID: 32172489 Free PMC article. Clinical Trial.
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, Schäfer-Eckart K, Krause SW, Hänel M, Herbst R, Kunzmann V, Einsele H, Jost E, Brümmendorf TH, Scholl S, Hochhaus A, Neubauer A, Sohlbach K, Fransecky L, Kaufmann M, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Stölzel F, von Bonin M, Middeke JM, Thiede C, Schetelig J, Berdel WE, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M. Röllig C, et al. Among authors: middeke jm. Blood. 2020 Aug 13;136(7):823-830. doi: 10.1182/blood.2019004583. Blood. 2020. PMID: 32496541 Free article.
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
Wermke M, Kraus S, Ehninger A, Bargou RC, Goebeler ME, Middeke JM, Kreissig C, von Bonin M, Koedam J, Pehl M, Bornhäuser M, Einsele H, Ehninger G, Cartellieri M. Wermke M, et al. Among authors: middeke jm. Blood. 2021 Jun 3;137(22):3145-3148. doi: 10.1182/blood.2020009759. Blood. 2021. PMID: 33624009 Free PMC article. No abstract available.
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Rautenberg C, Stölzel F, Röllig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, Verbeek M, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Severmann J, Wass M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Koch K, Henning L, Kobbe G, Haas R, Alakel N, Röhnert MA, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Heuser M, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Schroeder T, Middeke JM. Rautenberg C, et al. Among authors: middeke jm. Blood Cancer J. 2021 Oct 4;11(10):164. doi: 10.1038/s41408-021-00558-5. Blood Cancer J. 2021. PMID: 34608129 Free PMC article. Clinical Trial.
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
Middeke JM, Metzeler KH, Röllig C, Krämer M, Eckardt JN, Stasik S, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Krämer A, Hochhaus A, Brümmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Görlich D, Sauerland C, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Kaufmann M, Kunadt D, Wörmann B, Sockel K, von Bonin M, Herold T, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Baldus CD, Ehninger G, Schetelig J, Hiddemann W, Bornhäuser M, Stölzel F, Thiede C. Middeke JM, et al. Blood Adv. 2022 Mar 8;6(5):1394-1405. doi: 10.1182/bloodadvances.2021004934. Blood Adv. 2022. PMID: 34794176 Free PMC article.
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment.
Teipel R, Kroschinsky F, Kramer M, Kretschmann T, Egger-Heidrich K, Krüger T, Ruhnke L, Herold S, Stasik S, Sockel K, Middeke JM, Trautmann-Grill K, Bornhäuser M, Thiede C, von Bonin M. Teipel R, et al. Among authors: middeke jm. Blood Adv. 2022 Mar 22;6(6):1941-1946. doi: 10.1182/bloodadvances.2021005747. Blood Adv. 2022. PMID: 35008107 Free PMC article.
Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.
Stasik S, Burkhard-Meier C, Kramer M, Middeke JM, Oelschlaegel U, Sockel K, Ehninger G, Serve H, Müller-Tidow C, Baldus CD, Röllig C, Bornhäuser M, Platzbecker U, Thiede C. Stasik S, et al. Among authors: middeke jm. Blood Adv. 2022 Jun 14;6(11):3294-3303. doi: 10.1182/bloodadvances.2021006233. Blood Adv. 2022. PMID: 35320339 Free PMC article.
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M. Bornhäuser M, et al. Among authors: middeke jm. JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605. JAMA Oncol. 2023. PMID: 36757706 Free PMC article. Clinical Trial.
95 results